Start Over

Drug and gut microbe relationships: Moving beyond antibiotics.

Authors :: Kumbhare SV
Pedroso I
Ugalde JA
Márquez-Miranda V
Sinha R
Almonacid DE
Source :: Drug discovery today [Drug Discov Today] 2023 Nov; Vol. 28 (11), pp. 103797. Date of Electronic Publication: 2023 Oct 06.
Publication Year :: 2023
Abstract: Our understanding of drug-microbe relationships has evolved from viewing microbes as mere drug producers to a dynamic, modifiable system where they can serve as drugs or targets of precision pharmacology. This review highlights recent findings on the gut microbiome, particularly focusing on four aspects of research: (i) drugs for bugs, covering recent strategies for targeting gut pathogens; (ii) bugs as drugs, including probiotics; (iii) drugs from bugs, including postbiotics; and (iv) bugs and drugs, discussing additional types of drug-microbe interactions. This review provides a perspective on future translational research, including efficient companion diagnostics in pharmaceutical interventions.<br />Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: ‘All authors, except for J.A.U. and V.M.M., were employees of Digbi Health and may hold stocks or stock options in Digbi Health. R.S. was the CEO and founder of Digbi Health. D.E.A. has received royalties from Kura Biotech. S.V.K., I.P., R.S., and D.E.A. have patents pending related to the topic of this review (US Applications 17/817,558 and 17/817,562, entitled Methods and Systems for Multi-omics Interventions; and US Application 18/299,571, entitled Methods and Systems for Multi-omics Interventions for Multiple Health Conditions), as well as one provisional patent application (US Application 63/482,796, entitled Methods and Systems for Multi-omics Stratification of Patient Populations). I.P., J.A.U., V.M.M., and D.E.A. have coauthored multiple patents and patents pending owned by third-party companies, which are available in public domain repositories. The former conflicts of interest did not influence our adherence to policies nor any of the concepts or opinions discussed in this review article, and the review does not focus unduly on our own research or products.’.<br /> (Copyright © 2023 Elsevier Ltd. All rights reserved.)